Pfizer, Astellas announces FDA approval of PADCEV plus Keytruda in MIBC
Pfizer (PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration has approved PADCEV, a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor, Keytruda or Keytruda QLEX as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer regardless of ci